Histone Deacetylase Inhibitors Improve Memory Function and Decrease Neuropathology in APP/PS1 Mice

The brain is not a static machine; it is a living landscape that changes as we age. In a healthy mind, the instructions for building and maintaining the connections between nerve cells are written in a code that can be turned on or off. This code is wrapped around spools of protein called histones. When these spools are tightly wound, the instructions are hidden and the genes are silent. When they are loosened, the instructions are accessible, and the genes can be read to build the proteins needed for memory and learning. In conditions like Alzheimer's disease and during normal aging, a specific group of enzymes, known as histone deacetylases, acts like a pair of scissors that snips the chemical tags holding these spools open. This causes the genetic instructions to get wrapped up too tightly, silencing the very genes the brain needs to function. Scientists have long wondered if they could use drugs to stop these enzymes, effectively re-opening the genetic code to restore memory and slow the disease.

A new study from researchers at Northwestern University takes a closer look at how different types of these drugs work in mice that model Alzheimer's disease. The team tested three different compounds: one broad-spectrum drug that stops many types of enzymes at once, and two more precise drugs that target only specific versions of the enzyme. They gave these drugs to mice at different ages, ranging from young adults to the equivalent of elderly humans, and then watched how the animals performed on memory tests. The results revealed that not all drugs are created equal. While the broad-spectrum drug did little to help, the two precise drugs worked wonders, but they helped the brain in different ways and in different places. One drug acted like a key for the hippocampus, the brain's center for long-term spatial memory, while the other acted on the prefrontal cortex, the area responsible for recognizing objects and holding short-term information.

The researchers began by looking at mice that carry the genetic mutations responsible for Alzheimer's disease in humans. These mice develop memory problems and brain plaques as they age, much like people do. The team divided the mice into groups and treated them for thirty days with either a broad-spectrum inhibitor called valproic acid, or one of the two selective inhibitors, entinostat or tacedinaline. After the treatment period, the mice were put through a series of memory challenges. In one test, they were shown two identical objects and then later shown one familiar object and one new one. A mouse with good memory would spend more time exploring the new object. In another test, the mice navigated a Y-shaped maze to see if they could remember which path they had just taken. Finally, they were placed in a pool of water to see if they could remember the location of a hidden platform, a test of long-term spatial memory.

The results were striking. The broad-spectrum drug, valproic acid, failed to improve memory in any of the mice, regardless of their age or disease status. However, the two selective drugs produced clear benefits. Both tacedinaline and entinostat significantly improved the ability of older mice with Alzheimer's-like symptoms to recognize new objects and remember recent paths. Tacedinaline also restored their long-term spatial memory, allowing them to remember the location of the hidden platform, whereas entinostat did not restore this specific type of memory. Crucially, neither drug improved the memory of healthy, aging mice that did not have the disease, suggesting that these treatments work by fixing a specific breakdown in the brain's machinery rather than simply boosting a healthy brain to superhuman levels.

To understand why these drugs worked differently, the scientists looked inside the brains of the mice. They examined the hippocampus and the prefrontal cortex, two regions critical for memory. They found that in the mice treated with tacedinaline, the genes responsible for building synapses—the connections between nerve cells—were turned back on specifically in the hippocampus. This region is where long-term memories are stored. The drug worked by loosening the tight wrapping around these genes, allowing the brain to produce the proteins needed for learning. In contrast, the drug entinostat turned on these same genes, but primarily in the prefrontal cortex. This area is involved in recognizing objects and holding information for a few seconds. The researchers confirmed that the drugs were working by adding chemical tags to the DNA, which acted as a signal to keep the genes active. This process, known as histone acetylation, was the mechanism that allowed the brain to recover its ability to form memories.

Beyond memory, the study also looked at the physical damage caused by the disease. In Alzheimer's, clumps of protein called amyloid plaques build up in the brain, and immune cells called microglia become overactive, causing inflammation. The researchers found that entinostat was particularly effective at reducing the number of these amyloid plaques in both the hippocampus and the prefrontal cortex. It did this not by stopping the production of the plaque-forming protein, but by increasing the activity of an enzyme that breaks down the plaques. Both selective drugs also calmed the overactive immune cells, reducing the inflammation that damages brain tissue. The broad-spectrum drug, however, had no effect on these pathological markers.

The study concludes that the brain is not a single unit that reacts uniformly to treatment. Instead, different parts of the brain rely on different versions of the enzyme that the drugs target. One version of the enzyme, found mostly in the hippocampus, seems to be the main culprit in the loss of long-term spatial memory, and blocking it with tacedinaline restores that function. Another version, found in the prefrontal cortex, is linked to recognition and short-term memory, and blocking it with entinostat helps in that domain. Furthermore, the drug that targets the prefrontal cortex also appears to have a unique ability to clear away the toxic protein plaques that characterize the disease. These findings suggest that a one-size-fits-all approach to treating Alzheimer's may not be the most effective path. Instead, targeting specific enzymes in specific brain regions could offer a more precise way to restore memory and reduce disease damage, offering a new hope for therapies that address the complex, regional nature of the disease.